Page last updated: 2024-11-09

bis(pinacolato)diboron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2733548
CHEBI ID183312
SCHEMBL ID11221
MeSH IDM0436589

Synonyms (118)

Synonym
AC-1854
bis(pinacolato)diborane
CHEBI:183312
pinacol diborane
4,4',5,5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane
dipinacoldiboron
diboron pinacol ester
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane)
4,4,5,5,4',4',5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
bis(pinacolato) diborate
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolan
4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
b2pin2
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1,3,2-dioxaborolane
bis(pinacolate)diboron
octamethyl-2,2'-bi(1,3,2-dioxaborolane)
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
bis(pinacolato)diboron, 99%
73183-34-3
bis(pinacolato)diboron ,
B1964 ,
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane
FT-0654112
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane
A837739 ,
AKOS005259663
EN300-57239
4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane
bis(2,2,3,3-tetramethyl-2,3-butanedionato)diboron
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bl-1,3,2-dioxaborolane
bis(pinacolato) diboron
2,2'-bi-1,3,2-dioxaborlane,4,4,4',4',5,5,5',5'-octamethyl-dimethylamine
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl]
AM62774
2,2'-bi-1,3,2-dioxaborolane, 4,4,4',4',5,5,5',5'-octamethyl-
FT-0623090
AS-2373
AB07251
BP-21254
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane
unii-i906w26p4u
bis(pinacolato)diborane [mi]
i906w26p4u ,
ec 615-925-0
miyaura's reagent
78183-34-3
4,4,5,5,4',4',5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolanyl
pin2b2
bis(pinacolato) diborane
4,4,4',4',5,5,5',5'-octa-methyl-2,2'-bi(1,3,2-dioxaborolane)
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-yl))-1,3,2-dioxaborolane
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxa-borolane
4,4,5,5,4',4',5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2 ]dioxaborolanyl]
bis(pina-colato)diboron
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxa borolane)
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2- dioxaborolane)
bis (pinacolato)diboron
bispinacolate diboron
4,4,5,5,4',4',5',5'-octamethyl-[2,2]-bi[[1,3,2]dioxaborolanyl]
4,4,5,5,4',4',5',5'-octamethyl-2,2'-bi(1,3,2)dioxaborolane
bis-pinacolate diboron
octamethyl-2,2'-bi-1,3,2-dioxaborolane
4,4,4',4',5,5,5',5' -octamethyl-2,2'-bi(1,3,2-dioxaborolane)
4,4,5,5,4',4',5',5'-octamethyl[2,2']bi[[1,3,2]dioxaborolanyl]
bis (pinacolato)diborane
4,4,4',4',5 ,5 ,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-(1,3,2-dioxaborolane)
bis (pinacolato) diborane
bis(pinacolatodiboron)
4,4,5,5,4',4',5',5'-octamethyl-[2,2']-bi[[1,3,2]dioxaborolanyl]
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]-dioxaborolanyl]
bis(pina colato)diboron
4,4,4',4',5,5,5',5'-octamethyl-2,2-bi-1,3,2-dioxaborolane
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2] dioxaborolanyl]
bis (pinacolato) diboron
4,4,4',4',5,5,5',5'-octamethyl 2,2'-bi-1,3,2-dioxaborolane
bis(pinacol-ato)diboron
4,4,4',4',5,5,5',5'-octamethyl[2,2'-bi-1,3,2-dioxaborolane]
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2 dioxaborolane)
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)-1,3,2-dioxaborolane
4,4,5,5,-tetramethyl-2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane
4,4,4',4', 5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
bis(pi nacolatodiboron)
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxa-borolane)
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi (1,3,2-dioxaborolane)
bis-(pinacolato) diboron
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi1,3,2-dioxaborolane
4,4,5,5,4',4',5',5'-octamethyl-[2,2]bi[[1,3,2]dioxaborolanyl]
4,4,5,5-tetramethyl-2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane
4,4,5,5,4',4',5',5'-octamethyl-2,2'bi[1,3,2-dioxaborolanyl]
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[(1,3,2)dioxaborolanyl]
bis-(pinacolato)diboron
4,4,4', 4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
IPWKHHSGDUIRAH-UHFFFAOYSA-N
4,4,4',4',5,5,5'5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[1,3,2]dioxaborolanyl
4,4,5,5,4',4',5',5'-octamethyl-2,2'-bi[[1,3,2]dioxaborolanyl]
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxa-borolane)
dipinacol-diboron
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl (1,3,2-dioxaborolan-2-yl))-1,3,2-dioxaborolane
SCHEMBL11221
STL415055
Q-200724
mfcd00799570
F0001-1852
DTXSID30369935
CS-D1216
SY001323
BCP07115
Q4917161
bis(pinacolate)diborane(4)
4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-4',4',5', 5'-tetramethyl-1',3',2'-dioxaborolane
OL10114
bis(pinacolato)dibrorn
l-phenylalanine,l-threonyl-l-histidyl-l-threonyl-l-asparaginyl-l-isoleucyl-l-seryl-l-a-glutamyl-l-seryl-l-histidyl-l-prolyl-l-asparaginyl-l-alanyl-l-threonyl-
HY-79444
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.4.24.24 (gelatinase A) inhibitorAn EC 3.4.24.* (metalloendopeptidase) inhibitor that interferes with the action of gelatinase A (EC 3.4.24.24).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1,3,2-dioxaborolaneMembers of the class of boronate ester that include compounds containing a five-membered ring boronic ester.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (70.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.94 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index93.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]